Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.

被引：0
|
作者：
Li, Jinpeng
Chen, Hua
Song, Jinlong
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Intervent Ward One, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16134
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study
    Li, Jinpeng
    Li, Yan
    Song, Jinlong
    Zhao, Lujun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1207 - 1219
  • [2] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
    Cao, Yajuan
    Zhang, Xuebin
    Yue, Yang
    Peng, Jin
    Li, Binghua
    Shi, Jiong
    Tang, Min
    Chen, Chaobo
    Su, Ke
    Zhang, Laizhu
    Cheng, Chunxiao
    Yu, Decai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
  • [4] Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study
    Zhang, Zhibo
    Yan, Maolin
    Chen, Yufeng
    Wu, Xukun
    Yang, Lanfang
    Yin, Zhengyu
    Lu, Hao
    Zeng, Yongyi
    Zhang, Hui
    Huang, Jingyao
    Chen, Jiafei
    Wang, Liang
    Chen, Zhongwu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): A prospective, single-arm, phase II trial
    Peng, W.
    Hao, Y.
    Wei, Y.
    Xie, F.
    Li, C.
    Zhang, X.
    Shen, J.
    Lu, W.
    Zhou, J.
    Wen, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S668 - S668
  • [7] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
    Xu, Yongkang
    Fu, Shumin
    Mao, Ye
    Yi, Fengming
    Jiang, Weiming
    Feng, Long
    Wu, Jianbing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 500 - 500
  • [8] Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.
    Liu, Huan
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study
    Chen, Yiwen
    Zhang, Junlei
    Hu, Wendi
    Li, Xiang
    Sun, Ke
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [10] The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial
    Liang, Guo
    Gu, Shanzhi
    Guo, Yabing
    Li, Hailiang
    Liu, Jingfeng
    Liu, Jibing
    Huang, Ming
    Zou, Yinghua
    Huang, Luke
    Zhang, Yangyang
    Liu, Ting
    Liu, Wei
    Wang, Zhongmin
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 478 - 478
12345